Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TQH2722 injection in seasonal allergic rhinitis (Phase II, single-arm)
CTR20260277Phase 2Active
- Sponsor
- Nanjing Shunxin Pharmaceutical
- Start
- Mar 2026
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of TQH2722 in seasonal allergic rhinitis (SAR), sponsored by Nanjing Shunxin Pharmaceutical. Started Mar 2026; status: active.
02
Drugs
TQH2722
03
Conditions
seasonal allergic rhinitis (SAR)
Beyond the preview
Go deeper on CTR20260277.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20260277.